BioSpace News Archive

Certara, Inc., a global leader in biosimulation, announced that Company management will participate in the following investor conferences.

Belite Bio, Inc announced the closing of its previously announced initial public offering of 6 million American Depositary Shares at a public offering price per ADS of $6.00.

Vera Therapeutics, Inc. announced two oral presentations featuring new clinical data on the Company’s lead product candidate, atacicept, to be presented at the 59th European Renal Association – European Dialysis and Transplant Association Congress being held May 19-22, 2022 in Paris, France, in person and virtually, at the Paris Expo Porte de Versailles.

MiMedx Group, Inc., a transformational placental biologics company, announced the filing of its first quarter 2022 Form 10-Q for the period ended March 31, 2022.

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced that it will participate in the Bank of America Securities 2022 Healthcare Conference taking place May 9-13, 2022, in Las Vegas, NV.

SQZ Biotechnologies announced that Armon Sharei, Ph.D., Chief Executive Officer and Founder of SQZ Biotechnologies, will present at the Bank of America Securities 2022 Healthcare Conference on May 10, in Las Vegas, Nevada and at the H.C. Wainwright Global Investment Conference on May 25, in Miami, Florida.

Ultragenyx Pharmaceutical Inc. reported the grant of non-qualified stock options to purchase an aggregate of 20,480 shares of common stock of the company and 11,620 restricted stock units of the company’s common stock to two newly hired non-executive officers of the company.

Castle Biosciences, Inc. announced its ongoing collaboration with the Melanoma Research Foundation and The Skin Cancer Foundation to support skin cancer research, education and advocacy, highlighting events during May, in recognition of Skin Cancer Awareness Month.

Bioventus Inc., a global leader in innovations for active healing, announced that its subsidiary, Bioventus LLC, has withdrawn its offering of senior notes that was announced on Tuesday, April 26, 2022.

Coherus BioSciences, Inc., announced that effective April 27, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 240,000 shares of the common stock of the Company to 13 newly hired employees with a per share exercise price of $9.28, the closing trading price on the grant date.